Menzel Garry E's Form 4 filing
TCR2 Therapeutics Inc. (TCRR) · filed Dec 13, 2022
- Accession no.
- 0000899243-22-038380
- Filed
- Dec 13, 2022
- Trade date
- Dec 9-13, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $35.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Menzel Garry ECIK 0001556064 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 9, 2022 | Common Stock | SSaleDisposed | −10,325 | $1.13 | −$11,667.25 | 160,484 | Direct | |
| Dec 12, 2022 | Common Stock | SSaleDisposed | −10,613 | $1.10 | −$11,674.3 | 149,871 | Direct | |
| Dec 13, 2022 | Common Stock | SSaleDisposed | −11,000 | $1.06 | −$11,660 | 138,871 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.